Article Text

Download PDFPDF

744 Phase 1b/2, multicenter dose escalation and expansion study of muzastotug (ADG126, a masked anti-CTLA-4 SAFEbody®) in combination with pembrolizumab in advanced/metastatic MSS CRC
  1. Daneng Li1,
  2. Sun Young Kim2,
  3. Hee Kyung Kim3,
  4. Sunil Sharma4,
  5. Sang Shin5,
  6. Jeeyun Lee6,
  7. Seock-Ah Im7,
  8. Luke Chung8,
  9. Yan Li8,
  10. Ping Xiao9,
  11. John J Skinner9,
  12. Songmao Zheng10,
  13. Kristine Xiaohong She8,
  14. Dana D Hu-Lowe8,
  15. Michael Chisamore11,
  16. Peter Luo8,
  17. Jiping Zha8 and
  18. Manish R Patel12
  1. 1City of Hope National Medical Center, Duarte, CA, USA
  2. 2University of Ulsan College of Medicine, Seoul, Seoul, Republic of Korea
  3. 3Chungbuk National University Hospital, Cheongju, Cheongju, Republic of Korea
  4. 4Honor Health Research Institute, Scottsdale, AZ, USA
  5. 5Yonsei Cancer Center, Seoul, Republic of Korea
  6. 6Samsung Medical Center, Seoul, Republic of Korea
  7. 7Seoul National University Hospital, Seoul, Republic of Korea
  8. 8Adagene Inc., San Diego, CA, USA
  9. 9Adagene Inc., Suzhou, China
  10. 10Adagene Inc, West Harrison, IN, USA
  11. 11Merck and Co., Inc., Rahway, NJ, USA
  12. 12Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.

Abstract

Background Muzastotug is an anti-CTLA-4 IgG1 SAFEbody® with cleavable masking peptides that is preferentially activated in the tumor microenvironment and binds to a unique CTLA-4 epitope to prime T cells and deplete Tregs. We previously reported that repeated dosing of Muza as monotherapy had notably fewer Grade 3/4 irAEs than ipilimumab at ~7-fold higher doses (NCT04645069 and Study ADG126-1002), and that Muza/Pembro combination demonstrated promising clinical efficacy in 3L MSS CRC patients free of liver metastasis (NCT05405595). We report additional safety and efficacy data including further dose optimization for the combination therapy.

Methods This is a Phase 1b/2, open-label, multicenter dose escalation (DE) and expansion (EXP) study. Primary endpoints were safety and tolerability. Secondary endpoints were PK, ADA, ORR, DCR, DOR and PFS. Exposure-response assessment and mPBPK modeling were conducted.

Results As of 5/21/2024, 64 patients were dosed with Muza/Pembro (table 1). 26.6% patients had ≥ 3 prior therapies and 7.8% patients had prior IO therapies. No DLT or Grade 4/5 TRAE was observed and MTD was not reached. Grade 3 TRAEs at 10 mg/kg Q3W was 17% (7/42); TRAEs of ≥ 10% were pruritis (26.3%), hypothyroidism (15.3%), diarrhea (12.5%) and fatigue (11.1%). Repeat dosing at 20 mg/kg Q3W was associated with 3 TRAEs (3/5): 1 Grade 3 hemolytic anemia, 1 Grade 2 pneumonitis and 1 Grade 2 cough.

In MSS CRC EXP cohorts, Muza (10 mg/kg Q3W)/Pembro treatment resulted in 5 PRs [4 confirmed, ORR=17% (5/29)] and 86% DCR. The median treatment cycles for both Muza and Pembro were 5 (2–18). Subgroup analysis reveals that patients without liver and peritoneal metastasis (evaluable=22) showed a better response, resulting in 23% ORR (95% CI: 8–45%), 86% DCR, 36% CBR, 7-month mPFS, and >90% patients without survival event at data cutoff.

Integrated quantitative analysis supports the regimen of a single Muza 20 mg/kg loading dose followed by 10 mg/kg Q3W to optimize therapeutic index of the combination therapy. Evaluation of safety and efficacy with this regimen in MSS CRC is ongoing and will be reported.

Conclusions Muzastotug (up to 10 mg/kg Q3W)/Pembro continues to be well-tolerated with meaningful clinical benefits and durability in 3L MSS CRC. A higher dose Muza (20 mg/kg) allows for a rapid reaching of plasma cleaved drug exposure associated with clinical efficacy and an acceptable safety profile when combined with pembrolizumab. This regimen potentially can offer a best-in-class treatment option for patients with advanced/metastasis MSS CRC.

Abstract 744 Table 1

Safety and efficacy evaluable patients by dose levels

http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.